Articles

Shire to acquire German pharma Jerini AG

Written byChris Anderson
| 2 min read

BASINGSTOKE, U.K.—With a cash burn rate threatening to eat up its remaining available cash, but also holding a European approval for its hereditary angioedema (HAE) drug Firazyr, German pharma company Jerini AG announced on July 3 it will sell the company to global specialist pharmaceutical concern Shire for E6.25 per share. The all-cash transaction values Jerini at E328 million or roughly $509 million, and represents a 71 percent premium of the prior day's per share price.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.